Liquid biopsies are non-invasive diagnostic tests that analyze blood or other body fluids to detect the presence of cancer-related biomarkers such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA).
They address the limitations of traditional tissue biopsies, which can be invasive, painful, and sometimes unavailable due to tumor location or accessibility.
These tests work by isolating and analyzing CTCs and cfDNA from a patient's blood sample. The isolated genetic material is then sequenced and analyzed for mutations, genomic alterations, or other indicators of cancer.
Manufacturing involves developing sensitive detection methods, such as cell isolation techniques (e.g., magnetic bead separation) and genetic sequencing technologies. These processes require specialized equipment and expertise in molecular biology and bioinformatics.
The build process includes sample collection, processing to isolate CTCs or cfDNA, amplification of DNA if necessary, sequencing, data analysis, and interpretation of results.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.